Avelox
(Moxifloxacin)ApprovedSmall molecule
BayerMoxifloxacin is an antibiotic used to treat bacterial infections, including respiratory infections, skin infections, and eye infections. It works by killing bacteria that cause these infections.[2] Avelox is currently approved and in use across 61 indications[4].[1]
Avelox is one of 902 small molecule programs targeting Tuberculosis. It is currently in Approved.
61
Indications
413
Total Trials
10
Active Trials
901
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 58 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Voltaren
NovartisPreclinical
Duragesic-100
CCephalon
Preclinical
Spravato
WWim Janssens
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Paracetamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cardiac Repolarization23 trials
Show 20 more trials
A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 1·NCT02637193·54 enrolled
Cardiac9 trials
Show 6 more trials
CAR7 trials
A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01787357·60 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01787357·60 enrolledShow 4 more trials
Pulmonary Tuberculosis5 trials
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Active, not recruiting·CCenters for Disease Control and Prevention·Phase 2/3·NCT05766267·288 enrolled
Show 2 more trials
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00396084·70 enrolled
Single Dose5 trials
68 more indications
Heart5 trials
Tuberculosis5 trials
Show 2 more trials
Women5 trials
Adult Subject4 trials
Show 1 more trial
TED4 trials
ART4 trials
ESS4 trials
Randomized4 trials
Female4 trials
Intravenous3 trials
Adult3 trials
Function3 trials
Safety and Efficacy3 trials
Endophthalmitis3 trials
Pneumonia3 trials
The Optimization of Mycoplasm Pneumonia Antibiotic Therapy
Completed·—·N/A·NCT01259141·208 enrolled
Bacterial Pneumonia3 trials
Treatment2 trials
Phase 12 trials
Appendicitis2 trials
Clinical Trial2 trials
TIA2 trials
Cataract2 trials
Chronic Bronchitis2 trials
Celecoxib1 trial
Fasting Conditions1 trial
Bio-equivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions
Completed·—·Phase 1·NCT02322619·26 enrolled
Cholecystitis1 trial
Azithromycin1 trial
Schizoaffective Disorder1 trial
Smokers1 trial
Transplantation1 trial
Effect of Drugs1 trial
Cystic Fibrosis1 trial
Acute1 trial
Intraoperative1 trial
Pregnancy1 trial
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT00042289·1,578 enrolled
Conjunctivitis1 trial
Long QT Syndrome1 trial
Pelvic Inflammatory Disease1 trial
Blood Pressure1 trial
Pulmonary TB1 trial
Concentration1 trial
Parkinson's Disease1 trial
Liver abscess1 trial
Double-blind1 trial
Cardiovascular1 trial
Bacterial Conjunctivitis1 trial
Idiopathic Parkinson's Disease1 trial
Liver Resection1 trial
Chronic Periodontitis1 trial
Mycobacterium1 trial
Treatment of Mycobacterium Xenopi Pulmonary Infection
Completed·—·Phase 3·NCT01298336·92 enrolled
Experimental1 trial
Fed1 trial
Unspecified33 trials
Show 30 more trials
Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01674218·74 enrolled
Regulatory
FDA Approval Timeline[5]
Dec 10, 1999
AVELOX
NDA NDA021085
Nov 30, 2001
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER
NDA NDA021277
Apr 15, 2003
VIGAMOX
NDA NDA021598
Nov 19, 2010
MOXEZA
NDA NDA022428
Apr 3, 2015
MOXIFLOXACIN HYDROCHLORIDE
NDA NDA205572
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Avelox drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Moxifloxacin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Avelox. U.S. Food & Drug Administration.
- [7]